



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/922,490	08/03/2001	Richard J. Cristiano	INRP:021USC1	8065

7590 12/20/2004

Steven L. Highlander, Esq.
FULBRIGHT & JAWORSKI L.L.P.
Suite 2400
600 Congress Avenue
Austin, TX 78701

EXAMINER

NGUYEN, DAVE TRONG

ART UNIT PAPER NUMBER

1632

DATE MAILED: 12/20/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Supplemental Examiner's Amendment:

Authorization for this examiner's amendment was given in a telephone interview with Attorney Monica A. De La Paz on December 15, 2004.

This supplemental examiner 's amendment is to correct typographical errors present on original claims 3, 18, 19, 32, 33, 44 and 45, which result into improper dependency and antecedent basis. Note also that for the record, page 2 of the notice of allowance dated December 19, 2003 also contains a typographical error with respect to cancellation of claim 51. Claim 51 was not at al pending in the case.

In claim original claim 3, the claim has been rewritten as follows:

3. (Amended) The method of claim 2 1, wherein said target cell is a tumor cell.

18. (Amended) The method of claim 17, wherein said tumor target neoplastic cell is cisplatin sensitive.

19. (Amended) The method of claim 17, wherein said tumor target neoplastic cell is cisplatin insensitive.

32. (Amended) The method of claim 32 31, further comprising removing said DNA-damaging agent from said target neoplastic cell and transferring said transgene

into said target neoplastic cell between greater than about 1 day and less than or equal to 3 days after removing said DNA damaging agent.

33. (Amended) The method of claim 32, wherein said ~~tumor~~ target neoplastic cell is cisplatin insensitive.

44. (Amended) The method of claim 32 31, wherein said DNA-damaging agent is removed from said target neoplastic cell and wherein said transgene is transferred into said target neoplastic cell between greater than about 1 day and less than or equal to 3 days after removing said DNA-damaging agent.

45 (Amended) The method of claim 16, wherein said contacting of said DNA-damaging agent with said target dividing cell is discontinued by ceasing administration of said DNA-damaging agent.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner *Dave Nguyen* whose telephone number is **571-272-0731**.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, *Amy Nelson*, may be reached at 571-272-0804.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center number, which is **703-872-9306**.

Any inquiry of a general nature or relating to the status of this application should be directed to the *Group receptionist* whose telephone number is (703) 308-0196.

Dave Nguyen
Primary Examiner
Art Unit: 1632